Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro

Targeted Oncology

Volumn 8, Issue 4, 2013, Pages 281-290

  Jaszberenyi, Miklos ^a,b,c,d   Schally, Andrew V ^a,b,c   Block, Norman L ^a,b,c   Zarandi, Marta ^a,b,c   Cai, Ren Zhi ^a,b,c   Vidaurre, Irving ^a,b   Szalontay, Luca ^a,b   Jayakumar, Arumugam R ^a,b,c   Rick, Ferenc G ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b South Florida VA Foundation for Research and Education   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Glioblastoma multiforme; Growth hormone releasing hormone; Nude mice; Targeted therapy; U 87 MG

Indexed keywords

ANGIOPOIETIN 1; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; BETA CATENIN; CALVASCULIN; CD146 ANTIGEN; FIBROBLAST GROWTH FACTOR; GAMMA SYNUCLEIN; I KAPPA B ALPHA; INTEGRIN; INTERSTITIAL COLLAGENASE; METASTASIS SUPPRESSOR 1 PROTEIN; MIA 604; MIA 690; MITOGEN ACTIVATED PROTEIN KINASE 1; PLATELET DERIVED GROWTH FACTOR B; PROTEASE NEXIN; PROTEIN BCL 2; PROTEIN C JUN; PROTEIN P53; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; TUMOR NECROSIS FACTOR RECEPTOR 1A; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CELL ASSAY; CELL SIZE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEOMICS; TUMOR INVASION; TUMOR VASCULARIZATION; UPREGULATION;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; GLIOBLASTOMA; GROWTH HORMONE-RELEASING HORMONE; HUMANS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890568539     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-013-0264-y     Document Type: Article

References (64)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996. doi: 10.1056/NEJMoa043330
2. Barabutis N, Schally AV (2010) Growth hormone-releasing hormone: extrapituitary effects in physiology and pathology. Cell Cycle 9(20):4110-4116
3. Engel JB, Schally AV (2007) Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 3(2):157-167. doi: 10.1038/ncpendmet0399
4. Schally AV, Varga JL, Engel JB (2008) Antagonists of growth-hormone- releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 4(1):33-43. doi: 10.1038/ncpendmet0677
5. Schally AV, Nagy A (2003) New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 72(21):2305-2320
6. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL, Halmos G (2001) Hypothalamic hormones and cancer. Front Neuroendocrinol 22(4):248-291. doi: 10.1006/frne.2001.0217
7. Rick FG, Buchholz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Aigner E, Perez R, Seitz S, Block NL, Hohla F (2012) Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. Cell Cycle 11(13):2518-2525. doi: 10.4161/cc.20900
8. Hohla F, Buchholz S, Schally AV, Krishan A, Rick FG, Szalontay L, Papadia A, Halmos G, Koster F, Aigner E, Datz C, Seitz S (2010) Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. Cancer Lett 294(1):35-42. doi: 10.1016/j.canlet.2010.01.018
9. Treszl A, Schally AV, Seitz S, Szalontay L, Rick FG, Szepeshazi K, Halmos G (2009) Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162. Peptides 30(9):1643-1650. doi: 10.1016/j.peptides.2009.06.007
10. Szepeshazi K, Schally AV, Rick FG, Block NL, Vidaurre I, Halmos G, Szalontay L (2012) Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II. Anticancer Drugs 23(9):906-913. doi: 10.1097/CAD.0b013e328354bd25
11. Rick FG, Schally AV, Block NL, Nadji M, Szepeshazi K, Zarandi M, Vidaurre I, Perez R, Halmos G, Szalontay L (2011) Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci U S A 108(9):3755-3760. doi: 10.1073/pnas.1018086108
12. Rick FG, Szalontay L, Schally AV, Block NL, Nadji M, Szepeshazi K, Vidaurre I, Zarandi M, Kovacs M, Rekasi Z (2012) Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. J Urol 187(4):1498-1504. doi: 10.1016/j.juro.2011.11.081
13. Pozsgai E, Schally AV, Zarandi M, Varga JL, Vidaurre I, Bellyei S (2010) The effect of GHRH antagonists on human glioblastomas and their mechanism of action. Int J Cancer 127(10):2313-2322. doi: 10.1002/ijc.25259
14. Garcia-Fernandez MO, Schally AV, Varga JL, Groot K, Busto R (2003) The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation. Breast Cancer Res Treat 77(1):15-26
15. Klukovits A, Schally AV, Szalontay L, Vidaurre I, Papadia A, Zarandi M, Varga JL, Block NL, Halmos G (2012) Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers. Cancer 118(3):670-680. doi: 10.1002/cncr.26291
16. Rick FG, Schally AV, Szalontay L, Block NL, Szepeshazi K, Nadji M, Zarandi M, Hohla F, Buchholz S, Seitz S (2012) Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proc Natl Acad Sci U S A 109(5):1655-1660. doi: 10.1073/pnas.1120588109
17. Pozsgai E, Schally AV, Hocsak E, Zarandi M, Rick F, Bellyei S (2011) The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines. Int J Oncol 39(4):1025-1032. doi: 10.3892/ijo.2011.1098
18. Perez R, Schally AV, Vidaurre I, Rincon R, Block NL, Rick FG (2012) Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers. Oncotarget 3(9):988-997
19. Papadia A, Schally AV, Halmos G, Varga JL, Seitz S, Buchholz S, Rick F, Zarandi M, Bellyei S, Treszl A, Szalontay L, Lucci JA (2011) Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer. Horm Metab Res 43(11):816-820. doi: 10.1055/s-0031-1287766
20. Jaszberenyi M, Rick FG, Szalontay L, Block NL, Zarandi M, Cai RZ, Schally AV (2012) Beneficial effects of novel antagonists of GHRH in different models of Alzheimer's disease. Aging 4(11):755-767
21. Mareel M, Leroy A (2003) Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 83(2):337-376. doi: 10.1152/physrev.00024.2002
22. Bredesen DE, Rao RV, Mehlen P (2006) Cell death in the nervous system. Nature 443(7113):796-802. doi: 10.1038/nature05293
23. Notte A, Leclere L, Michiels C (2011) Autophagy as a mediator of chemotherapy-induced cell death in cancer. Biochem Pharmacol 82(5):427-434. doi: 10.1016/j.bcp. 2011.06.015
24. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91(3):1071-1121. doi: 10.1152/physrev.00038.2010
25. Kiaris H, Schally AV, Varga JL, Groot K, Armatis P (1999) Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma. Proc Natl Acad Sci U S A 96(26):14894-14898
26. Kiaris H, Schally AV, Varga JL (2000) Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice. Neoplasia 2(3):242-250
27. Kovacs M, Schally AV, Hohla F, Rick FG, Pozsgai E, Szalontay L, Varga JL, Zarandi M (2010) A correlation of endocrine and anticancer effects of some antagonists of GHRH. Peptides 31(10):1839-1846. doi: 10.1016/j.peptides.2010.07. 006
28. Jaeger LB, Banks WA, Varga JL, Schally AV (2005) Antagonists of growth hormone-releasing hormone cross the blood-brain barrier: a potential applicability to treatment of brain tumors. Proc Natl Acad Sci U S A 102(35):12495-12500. doi: 10.1073/pnas.0504163102
29. Ozawa T, James CD (2010) Establishing intracranial brain tumor xenografts with subsequent analysis of tumor growth and response to therapy using bioluminescence imaging. J Vis Exp(41). doi: 10.3791/1986
30. Shankavaram UT, Bredel M, Burgan WE, Carter D, Tofilon P, Camphausen K (2012) Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma. J Cell Mol Med 16(3):545-554. doi: 10.1111/j.1582-4934.2011.01345.x
31. Baumann BC, Dorsey JF, Benci JL, Joh DY, Kao GD (2012) Stereotactic intracranial implantation and in vivo bioluminescent imaging of tumor xenografts in a mouse model system of glioblastoma multiforme. J Vis Exp Sept 25(67). doi: 10.3791/4089
32. Ludwig B, Ziegler CG, Schally AV, Richter C, Steffen A, Jabs N, Funk RH, Brendel MD, Block NL, Ehrhart-Bornstein M, Bornstein SR (2010) Agonist of growth hormone-releasing hormone as a potential effector for survival and proliferation of pancreatic islets. Proc Natl Acad Sci U S A 107(28):12623-12628. doi: 10.1073/pnas.1005098107
33. Kondo Y, Kanzawa T, Sawaya R, Kondo S (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5(9):726-734. doi: 10.1038/nrc1692
34. Lefranc F, Kiss R (2006) Autophagy, the Trojan horse to combat glioblastomas. Neurosurg Focus 20(4):E7. doi: 10.3171/foc.2006.20.4.4
35. Siejka A, Barabutis N, Schally AV (2011) GHRH antagonist MZ-5-156 increases the expression of AMPK in A549 lung cancer cells. Cell Cycle 10(21):3714-3718. doi: 10.4161/cc.10.21.17904
36. Igney FH, Krammer PH (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2(4):277-288. doi: 10.1038/nrc776
37. Mizukawa K, Kawamura A, Sasayama T, Tanaka K, Kamei M, Sasaki M, Kohmura E (2006) Synthetic Smac peptide enhances the effect of etoposide-induced apoptosis in human glioblastoma cell lines. J Neurooncol 77(3):247-255. doi: 10.1007/s11060-005-9045-5
38. Jeuken J, van den Broecke C, Gijsen S, Boots-Sprenger S, Wesseling P (2007) RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol 114(2):121-133. doi: 10.1007/s00401-007-0239-0
39. Golestaneh N, Mishra B (2005) TGF-beta, neuronal stem cells and glioblastoma. Oncogene 24(37):5722-5730. doi: 10.1038/sj.onc.1208925
40. Galardi S, Mercatelli N, Farace MG, Ciafre SA (2011) NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. Nucleic Acids Res 39(9):3892-3902. doi: 10.1093/nar/gkr006
41. Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441(7092):431-436. doi: 10.1038/nature04870
42. Gyrd-Hansen M, Meier P (2010) IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 10(8):561-574. doi: 10.1038/nrc2889
43. Dawson JC, Timpson P, Kalna G, Machesky LM (2011) Mtss1 regulates epidermal growth factor signaling in head and neck squamous carcinoma cells. Oncogene. doi: 10.1038/onc.2011.376
44. Ritchie CK, Giordano A, Khalili K (2000) Integrin involvement in glioblastoma multiforme: possible regulation by NF-kappaB. J Cell Physiol 184(2):214-221. doi:10.1002/1097-4652(200008)184:2<214
45. Koul D, Shen R, Bergh S, Lu Y, de Groot JF, Liu TJ, Mills GB, Yung WK (2005) Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther 4(11):1681-1688. doi: 10.1158/1535-7163.MCT-05-0258
46. Riemenschneider MJ, Mueller W, Betensky RA, Mohapatra G, Louis DN (2005) In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation. Am J Pathol 167(5):1379-1387. doi: 10.1016/S0002-9440(10) 61225-4
47. Engel JB, Keller G, Schally AV, Toller GL, Groot K, Havt A, Armatis P, Zarandi M, Varga JL, Halmos G (2005) Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone. J Clin Endocrinol Metab 90(6):3614-3621. doi: 10.1210/jc.2004-2179
48. Heinrich E, Schally AV, Buchholz S, Rick FG, Halmos G, Mile M, Groot K, Hohla F, Zarandi M, Varga JL (2008) Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138. Prostate 68(16):1763-1772. doi: 10.1002/pros.20843
49. Stratmann A, Risau W, Plate KH (1998) Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153(5):1459-1466. doi: 10.1016/S0002-9440(10)65733-1
50. Ouhtit A, Gaur RL, Abd Elmageed ZY, Fernando A, Thouta R, Trappey AK, Abdraboh ME, El-Sayyad HI, Rao P, Raj MG (2009) Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146. Biochim Biophys Acta 1795(2):130-136. doi: 10.1016/j.bbcan.2009.01.002
51. Norden AD, Drappatz J, Wen PY (2009) Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 5(11):610-620. doi: 10.1038/nrneurol.2009.159
52. Kasza A, Kowanetz M, Poslednik K, Witek B, Kordula T, Koj A (2001) Epidermal growth factor and pro-inflammatory cytokines regulate the expression of components of plasminogen activation system in U373-MG astrocytoma cells. Cytokine 16(5):187-190. doi: 10.1006/cyto.2001.0957
53. Kunapuli P, Kasyapa CS, Hawthorn L, Cowell JK (2004) LGI1, a putative tumor metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathway. J Biol Chem 279(22):23151-23157. doi: 10.1074/jbc.M314192200
54. Bellyei S, Schally AV, Zarandi M, Varga JL, Vidaurre I, Pozsgai E (2010) GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro. Cancer Lett 293(1):31-40. doi: 10.1016/j.canlet.2009.12.014
55. Zhang H, Kouadio A, Cartledge D, Godwin AK (2011) Role of gamma-synuclein in microtubule regulation. Exp Cell Res 317(10):1330-1339. doi: 10.1016/j.yexcr.2010.10.013
56. Boye K, Maelandsmo GM (2010) S100A4 and metastasis: a small actor playing many roles. Am J Pathol 176(2):528-535. doi: 10.2353/ajpath.2010.090526
57. Wick W, Naumann U, Weller M (2006) Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. Curr Pharm Des 12(3):341-349
58. Hohla F, Schally AV, Szepeshazi K, Varga JL, Buchholz S, Koster F, Heinrich E, Halmos G, Rick FG, Kannadka C, Datz C, Kanashiro CA (2006) Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. Proc Natl Acad Sci U S A 103(39):14513-14518. doi: 10.1073/pnas.0605309103
59. Rick FG, Seitz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Buchholz S, Block NL, Hohla F (2012) GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer. Cell Cycle 11(22):4203-4210
60. Buchholz S, Schally AV, Engel JB, Hohla F, Heinrich E, Koester F, Varga JL, Halmos G (2007) Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Proc Natl Acad Sci U S A 104(6):1943-1946. doi: 10.1073/pnas.0610860104
61. Varga JL, Schally AV, Horvath JE, Kovacs M, Halmos G, Groot K, Toller GL, Rekasi Z, Zarandi M (2004) Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10. Proc Natl Acad Sci U S A 101(6):1708-1713. doi: 10.1073/pnas.0307288101
62. Pozsgai E, Schally AV, Halmos G, Rick F, Bellyei S (2010) The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma. Horm Metab Res 42(11):781-786. doi: 10.1055/s-0030-1261955
63. Kletzien RF, Pariza MW, Becker JE, Potter VR (1975) A method using 3-O-methyl-D-glucose and phloretin for the determination of intracellular water space of cells in monolayer culture. Anal Biochem 68(2):537-544
64. Bender AS, Norenberg MD (1998) Effect of benzodiazepines and neurosteroids on ammonia-induced swelling in cultured astrocytes. J Neurosci Res 54(5):673-680. doi: 10.1002/(SICI)1097-4547(19981201)54:5<673